Clairvoyant has received regulatory approval for its Phase 2 trial investigating psilocybin for the treatment of alcohol use disorder (AUD).
Awakn CEO, Anthony Tennyson, spoke to Psychedelic Health about the company’s plans to make ketamine therapy accessible to US patients.
LOVE Pharma’s trial will be exploring psilocybin-assisted therapy for cannabis use disorder (CUD), with Johns Hopkins University School of Medicine’s Dr Albert Garcia-Romeu serving as head...
Revive Therapeutics has announced that it is working on its first Phase I/II clinical study to evaluate oral psilocybin in the treatment of methamphetamine use disorder.
A study by researchers at NYU Grossman School of Medicine has found that two doses of psilocybin reduced heavy drinking by 83 per cent when combined...
Awakn Life Sciences has signed its first licensing partnership agreement in Canada with Ontario-based Wellbeings Pain Management and Dependency Clinic, which is focused on multi-disciplinary, evidence-based,...
Awakn Life Sciences is expanding its commercial operations into the US through its first licensing partnership with Revitalist Lifestyle and Wellness – one of the largest...
Origin Therapeutics has completed an investment in Clairvoyant Therapeutics which will now proceed with a Phase 2 clinical trial for the clinical validation of psilocybin for the treatment of alcohol use...
The UK’s national innovation agency – Innovate UK – has provided funding to Awakn Life Sciences to help bring its ketamine-assisted therapy to alcohol use disorder...
Awakn Life Sciences will be carrying out a follow-on behavioural study to focus on gambling disorder following its recent successful pilot study and patent filing.